IDXX vs LYEL · P/E 40, rev $2.36B vs rev $6.0K
IDEXX Laboratories Inc (IDXX) versus Lyell Immunopharma Inc (LYEL) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. LYEL currently screens at market cap $143.5M.
Not investment advice. Open the IDXX and LYEL stock pages for the full models.
Not investment advice.